Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Investigation into the use of histone deacetylase inhibitor MS-275 as a topical agent for the prevention and treatment of cutaneous squamous cell carcinoma in an SKH-1 hairless mouse model.

Kalin JH, Eroglu A, Liu H, Holtzclaw WD, Leigh I, Proby CM, Fahey JW, Cole PA, Dinkova-Kostova AT.

PLoS One. 2019 Mar 13;14(3):e0213095. doi: 10.1371/journal.pone.0213095. eCollection 2019.

2.

Measuring the Interaction of Transcription Factor Nrf2 with Its Negative Regulator Keap1 in Single Live Cells by an Improved FRET/FLIM Analysis.

Dikovskaya D, Appleton PL, Bento-Pereira C, Dinkova-Kostova AT.

Chem Res Toxicol. 2019 Mar 18;32(3):500-512. doi: 10.1021/acs.chemrestox.8b00354. Epub 2019 Mar 11.

PMID:
30793592
3.

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases.

Cuadrado A, Rojo AI, Wells G, Hayes JD, Cousin SP, Rumsey WL, Attucks OC, Franklin S, Levonen AL, Kensler TW, Dinkova-Kostova AT.

Nat Rev Drug Discov. 2019 Jan 4. doi: 10.1038/s41573-018-0008-x. [Epub ahead of print] Review.

PMID:
30610225
4.

A Defective Pentose Phosphate Pathway Reduces Inflammatory Macrophage Responses during Hypercholesterolemia.

Baardman J, Verberk SGS, Prange KHM, van Weeghel M, van der Velden S, Ryan DG, Wüst RCI, Neele AE, Speijer D, Denis SW, Witte ME, Houtkooper RH, O'neill LA, Knatko EV, Dinkova-Kostova AT, Lutgens E, de Winther MPJ, Van den Bossche J.

Cell Rep. 2018 Nov 20;25(8):2044-2052.e5. doi: 10.1016/j.celrep.2018.10.092.

5.

C151 in KEAP1 is the main cysteine sensor for the cyanoenone class of NRF2 activators, irrespective of molecular size or shape.

Dayalan Naidu S, Muramatsu A, Saito R, Asami S, Honda T, Hosoya T, Itoh K, Yamamoto M, Suzuki T, Dinkova-Kostova AT.

Sci Rep. 2018 May 23;8(1):8037. doi: 10.1038/s41598-018-26269-9.

6.

Phenethyl Isothiocyanate, a Dual Activator of Transcription Factors NRF2 and HSF1.

Dayalan Naidu S, Suzuki T, Yamamoto M, Fahey JW, Dinkova-Kostova AT.

Mol Nutr Food Res. 2018 Sep;62(18):e1700908. doi: 10.1002/mnfr.201700908. Epub 2018 Jun 19. Review.

7.

Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1.

Mills EL, Ryan DG, Prag HA, Dikovskaya D, Menon D, Zaslona Z, Jedrychowski MP, Costa ASH, Higgins M, Hams E, Szpyt J, Runtsch MC, King MS, McGouran JF, Fischer R, Kessler BM, McGettrick AF, Hughes MM, Carroll RG, Booty LM, Knatko EV, Meakin PJ, Ashford MLJ, Modis LK, Brunori G, Sévin DC, Fallon PG, Caldwell ST, Kunji ERS, Chouchani ET, Frezza C, Dinkova-Kostova AT, Hartley RC, Murphy MP, O'Neill LA.

Nature. 2018 Apr 5;556(7699):113-117. doi: 10.1038/nature25986. Epub 2018 Mar 28.

8.

Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).

Sharma RS, Harrison DJ, Kisielewski D, Cassidy DM, McNeilly AD, Gallagher JR, Walsh SV, Honda T, McCrimmon RJ, Dinkova-Kostova AT, Ashford MLJ, Dillon JF, Hayes JD.

Cell Mol Gastroenterol Hepatol. 2017 Dec 13;5(3):367-398. doi: 10.1016/j.jcmgh.2017.11.016. eCollection 2018 Mar.

9.

KEAP1 inhibition is neuroprotective and suppresses the development of epilepsy.

Shekh-Ahmad T, Eckel R, Dayalan Naidu S, Higgins M, Yamamoto M, Dinkova-Kostova AT, Kovac S, Abramov AY, Walker MC.

Brain. 2018 May 1;141(5):1390-1403. doi: 10.1093/brain/awy071.

PMID:
29538645
10.

Author Correction: Pathogenic p62/SQSTM1 mutations impair energy metabolism through limitation of mitochondrial substrates.

Bartolome F, Esteras N, Martin-Requero A, Boutoleau-Bretonniere C, Vercelletto M, Gabelle A, Ber IL, Honda T, Dinkova-Kostova AT, Hardy J, Carro E, Abramov AY.

Sci Rep. 2018 Mar 1;8(1):4064. doi: 10.1038/s41598-018-22152-9.

11.

The role of Nrf2 signaling in counteracting neurodegenerative diseases.

Dinkova-Kostova AT, Kostov RV, Kazantsev AG.

FEBS J. 2018 Oct;285(19):3576-3590. doi: 10.1111/febs.14379. Epub 2018 Jan 29. Review.

12.

Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors.

Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, Adejola N, Wu M, Panova I, Chung HJ, Kim E, Roberts HJ, Roberts JM, Prusevich P, Jeliazkov JR, Roy Burman SS, Fairall L, Milano C, Eroglu A, Proby CM, Dinkova-Kostova AT, Hancock WW, Gray JJ, Bradner JE, Valente S, Mai A, Anders NM, Rudek MA, Hu Y, Ryu B, Schwabe JWR, Mattevi A, Alani RM, Cole PA.

Nat Commun. 2018 Jan 4;9(1):53. doi: 10.1038/s41467-017-02242-4.

13.

KEAP1 and Done? Targeting the NRF2 Pathway with Sulforaphane.

Dinkova-Kostova AT, Fahey JW, Kostov RV, Kensler TW.

Trends Food Sci Technol. 2017 Nov;69(Pt B):257-269. doi: 10.1016/j.tifs.2017.02.002. Epub 2017 Feb 16.

14.
15.

Epigenetic Control of NRF2-Directed Cellular Antioxidant Status in Dictating Life-Death Decisions.

Hayes JD, Dinkova-Kostova AT.

Mol Cell. 2017 Oct 5;68(1):5-7. doi: 10.1016/j.molcel.2017.09.023.

16.

Transcription factors NRF2 and HSF1 have opposing functions in autophagy.

Dayalan Naidu S, Dikovskaya D, Gaurilcikaite E, Knatko EV, Healy ZR, Mohan H, Koh G, Laurell A, Ball G, Olagnier D, de la Vega L, Ganley IG, Talalay P, Dinkova-Kostova AT.

Sci Rep. 2017 Sep 8;7(1):11023. doi: 10.1038/s41598-017-11262-5.

17.

Metabolic and Homeostatic Changes in Seizures and Acquired Epilepsy-Mitochondria, Calcium Dynamics and Reactive Oxygen Species.

Kovac S, Dinkova Kostova AT, Herrmann AM, Melzer N, Meuth SG, Gorji A.

Int J Mol Sci. 2017 Sep 8;18(9). pii: E1935. doi: 10.3390/ijms18091935. Review.

18.

Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses.

Torrente L, Sanchez C, Moreno R, Chowdhry S, Cabello P, Isono K, Koseki H, Honda T, Hayes JD, Dinkova-Kostova AT, de la Vega L.

Oncogene. 2017 Nov 2;36(44):6204-6212. doi: 10.1038/onc.2017.221. Epub 2017 Jul 10.

19.

Oxidative stress management in the hair follicle: Could targeting NRF2 counter age-related hair disorders and beyond?

Jadkauskaite L, Coulombe PA, Schäfer M, Dinkova-Kostova AT, Paus R, Haslam IS.

Bioessays. 2017 Aug;39(8). doi: 10.1002/bies.201700029. Epub 2017 Jul 7. Review.

PMID:
28685843
20.

Oxidative stress and chronic inflammation in osteoarthritis: can NRF2 counteract these partners in crime?

Marchev AS, Dimitrova PA, Burns AJ, Kostov RV, Dinkova-Kostova AT, Georgiev MI.

Ann N Y Acad Sci. 2017 Aug;1401(1):114-135. doi: 10.1111/nyas.13407. Epub 2017 Jun 29. Review.

PMID:
28662306
21.

Activation of Nrf2 signaling as a common treatment of neurodegenerative diseases.

Dinkova-Kostova AT, Kazantsev AG.

Neurodegener Dis Manag. 2017 Apr;7(2):97-100. doi: 10.2217/nmt-2017-0011. Epub 2017 May 23. No abstract available.

22.

KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients.

Quinti L, Dayalan Naidu S, Träger U, Chen X, Kegel-Gleason K, Llères D, Connolly C, Chopra V, Low C, Moniot S, Sapp E, Tousley AR, Vodicka P, Van Kanegan MJ, Kaltenbach LS, Crawford LA, Fuszard M, Higgins M, Miller JRC, Farmer RE, Potluri V, Samajdar S, Meisel L, Zhang N, Snyder A, Stein R, Hersch SM, Ellerby LM, Weerapana E, Schwarzschild MA, Steegborn C, Leavitt BR, Degterev A, Tabrizi SJ, Lo DC, DiFiglia M, Thompson LM, Dinkova-Kostova AT, Kazantsev AG.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4676-E4685. doi: 10.1073/pnas.1614943114. Epub 2017 May 22.

23.

Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity.

Olagnier D, Lababidi RR, Hadj SB, Sze A, Liu Y, Naidu SD, Ferrari M, Jiang Y, Chiang C, Beljanski V, Goulet ML, Knatko EV, Dinkova-Kostova AT, Hiscott J, Lin R.

Mol Ther. 2017 Aug 2;25(8):1900-1916. doi: 10.1016/j.ymthe.2017.04.022. Epub 2017 May 17.

24.

Pathogenic p62/SQSTM1 mutations impair energy metabolism through limitation of mitochondrial substrates.

Bartolome F, Esteras N, Martin-Requero A, Boutoleau-Bretonniere C, Vercelletto M, Gabelle A, Le Ber I, Honda T, Dinkova-Kostova AT, Hardy J, Carro E, Abramov AY.

Sci Rep. 2017 May 10;7(1):1666. doi: 10.1038/s41598-017-01678-4. Erratum in: Sci Rep. 2018 Mar 1;8(1):4064.

25.

Flavonolignan 2,3-dehydrosilydianin activates Nrf2 and upregulates NAD(P)H:quinone oxidoreductase 1 in Hepa1c1c7 cells.

Roubalová L, Dinkova-Kostova AT, Biedermann D, Křen V, Ulrichová J, Vrba J.

Fitoterapia. 2017 Jun;119:115-120. doi: 10.1016/j.fitote.2017.04.012. Epub 2017 Apr 24.

26.

NRF2 as an Emerging Therapeutic Target.

Copple IM, Dinkova-Kostova AT, Kensler TW, Liby KT, Wigley WC.

Oxid Med Cell Longev. 2017;2017:8165458. doi: 10.1155/2017/8165458. Epub 2017 Jan 31. No abstract available.

27.

The multifaceted role of Nrf2 in mitochondrial function.

Holmström KM, Kostov RV, Dinkova-Kostova AT.

Curr Opin Toxicol. 2016 Dec;1:80-91. doi: 10.1016/j.cotox.2016.10.002. Review.

28.

Regulation of the mammalian heat shock factor 1.

Dayalan Naidu S, Dinkova-Kostova AT.

FEBS J. 2017 Jun;284(11):1606-1627. doi: 10.1111/febs.13999. Epub 2017 Feb 1. Review.

29.

Whole-Exome Sequencing Validates a Preclinical Mouse Model for the Prevention and Treatment of Cutaneous Squamous Cell Carcinoma.

Knatko EV, Praslicka B, Higgins M, Evans A, Purdie KJ, Harwood CA, Proby CM, Ooi A, Dinkova-Kostova AT.

Cancer Prev Res (Phila). 2017 Jan;10(1):67-75. doi: 10.1158/1940-6207.CAPR-16-0218. Epub 2016 Dec 6.

30.

Semisynthetic flavonoid 7-O-galloylquercetin activates Nrf2 and induces Nrf2-dependent gene expression in RAW264.7 and Hepa1c1c7 cells.

Roubalová L, Biedermann D, Papoušková B, Vacek J, Kuzma M, Křen V, Ulrichová J, Dinkova-Kostova AT, Vrba J.

Chem Biol Interact. 2016 Dec 25;260:58-66. doi: 10.1016/j.cbi.2016.10.015. Epub 2016 Oct 21.

31.

NAD(P)H:quinone oxidoreductase 1 inducer activity of some novel anilinoquinazoline derivatives.

Ghorab MM, Alsaid MS, Higgins M, Dinkova-Kostova AT, Shahat AA, Elghazawy NH, Arafa RK.

Drug Des Devel Ther. 2016 Aug 8;10:2515-24. doi: 10.2147/DDDT.S105423. eCollection 2016.

32.

Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidants.

Dinkova-Kostova AT, Kostov RV, Canning P.

Arch Biochem Biophys. 2017 Mar 1;617:84-93. doi: 10.1016/j.abb.2016.08.005. Epub 2016 Aug 3. Review.

33.

Electron affinity of tricyclic, bicyclic, and monocyclic compounds containing cyanoenones correlates with their potency as inducers of a cytoprotective enzyme.

Bensasson RV, Dinkova-Kostova AT, Zheng S, Saito A, Li W, Zoete V, Honda T.

Bioorg Med Chem Lett. 2016 Sep 1;26(17):4345-9. doi: 10.1016/j.bmcl.2016.07.028. Epub 2016 Jul 15.

PMID:
27460172
34.

SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models.

Quinti L, Casale M, Moniot S, Pais TF, Van Kanegan MJ, Kaltenbach LS, Pallos J, Lim RG, Naidu SD, Runne H, Meisel L, Rauf NA, Leyfer D, Maxwell MM, Saiah E, Landers JE, Luthi-Carter R, Abagyan R, Dinkova-Kostova AT, Steegborn C, Marsh JL, Lo DC, Thompson LM, Kazantsev AG.

Cell Chem Biol. 2016 Jul 21;23(7):849-861. doi: 10.1016/j.chembiol.2016.05.015. Epub 2016 Jul 14.

35.

Nrf2-Mediated Neuroprotection Against Recurrent Hypoglycemia Is Insufficient to Prevent Cognitive Impairment in a Rodent Model of Type 1 Diabetes.

McNeilly AD, Gallagher JR, Dinkova-Kostova AT, Hayes JD, Sharkey J, Ashford ML, McCrimmon RJ.

Diabetes. 2016 Oct;65(10):3151-60. doi: 10.2337/db15-1653. Epub 2016 Jul 13.

36.

Heat Shock Factor 1 Is a Substrate for p38 Mitogen-Activated Protein Kinases.

Dayalan Naidu S, Sutherland C, Zhang Y, Risco A, de la Vega L, Caunt CJ, Hastie CJ, Lamont DJ, Torrente L, Chowdhry S, Benjamin IJ, Keyse SM, Cuenda A, Dinkova-Kostova AT.

Mol Cell Biol. 2016 Aug 26;36(18):2403-17. doi: 10.1128/MCB.00292-16. Print 2016 Sep 15.

37.

Loss of Nrf2 abrogates the protective effect of Keap1 downregulation in a preclinical model of cutaneous squamous cell carcinoma.

Knatko EV, Higgins M, Fahey JW, Dinkova-Kostova AT.

Sci Rep. 2016 May 24;6:25804. doi: 10.1038/srep25804.

38.

Potency of extracts from selected Egyptian plants as inducers of the Nrf2-dependent chemopreventive enzyme NQO1.

Hamed AR, Hegazy ME, Higgins M, Mohamed TA, Abdel-Azim NS, Pare PW, Dinkova-Kostova AT.

J Nat Med. 2016 Jul;70(3):683-8. doi: 10.1007/s11418-016-0994-0. Epub 2016 Apr 27.

PMID:
27120175
39.

Synthesis, molecular modeling and NAD(P)H:quinone oxidoreductase 1 inducer activity of novel 2-phenylquinazolin-4-amine derivatives.

Ghorab MM, Alsaid MS, Higgins M, Dinkova-Kostova AT, Shahat AA, Elghazawy NH, Arafa RK.

J Enzyme Inhib Med Chem. 2016 Dec;31(6):1612-8. doi: 10.3109/14756366.2016.1158714. Epub 2016 Apr 7.

PMID:
27052554
40.
41.

Filaggrin genotype does not determine the skin's threshold to UV-induced erythema.

Forbes D, Johnston L, Gardner J, MacCallum SF, Campbell LE, Dinkova-Kostova AT, McLean WHI, Ibbotson SH, Dawe RS, Brown SJ.

J Allergy Clin Immunol. 2016 Apr;137(4):1280-1282.e3. doi: 10.1016/j.jaci.2015.11.022. Epub 2016 Jan 29. No abstract available.

42.

Nrf2 activation in the treatment of neurodegenerative diseases: a focus on its role in mitochondrial bioenergetics and function.

Esteras N, Dinkova-Kostova AT, Abramov AY.

Biol Chem. 2016 May;397(5):383-400. doi: 10.1515/hsz-2015-0295. Review.

PMID:
26812787
43.

NAD(P)H: quinone oxidoreductase 1 inducer activity of novel 4-aminoquinazoline derivatives.

Ghorab MM, Alsaid MS, El-Gazzar MG, Higgins M, Dinkova-Kostova AT, Shahat AA.

J Enzyme Inhib Med Chem. 2016 Dec;31(6):1369-74. doi: 10.3109/14756366.2015.1135913. Epub 2016 Jan 21.

PMID:
26796666
44.

Dual regulation of transcription factor Nrf2 by Keap1 and by the combined actions of β-TrCP and GSK-3.

Hayes JD, Chowdhry S, Dinkova-Kostova AT, Sutherland C.

Biochem Soc Trans. 2015 Aug;43(4):611-20. doi: 10.1042/BST20150011. Epub 2015 Aug 3. Review.

PMID:
26551701
45.

The spatiotemporal regulation of the Keap1-Nrf2 pathway and its importance in cellular bioenergetics.

Dinkova-Kostova AT, Baird L, Holmström KM, Meyer CJ, Abramov AY.

Biochem Soc Trans. 2015 Aug;43(4):602-10. doi: 10.1042/BST20150003. Epub 2015 Aug 3.

46.

Design, Synthesis, and Evaluation of Triazole Derivatives That Induce Nrf2 Dependent Gene Products and Inhibit the Keap1-Nrf2 Protein-Protein Interaction.

Bertrand HC, Schaap M, Baird L, Georgakopoulos ND, Fowkes A, Thiollier C, Kachi H, Dinkova-Kostova AT, Wells G.

J Med Chem. 2015 Sep 24;58(18):7186-94. doi: 10.1021/acs.jmedchem.5b00602.

PMID:
26348784
47.

Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action.

Kostov RV, Knatko EV, McLaughlin LA, Henderson CJ, Zheng S, Huang JT, Honda T, Dinkova-Kostova AT.

Biochem Biophys Res Commun. 2015 Sep 25;465(3):402-7. doi: 10.1016/j.bbrc.2015.08.016. Epub 2015 Aug 8.

48.

Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease.

Tebay LE, Robertson H, Durant ST, Vitale SR, Penning TM, Dinkova-Kostova AT, Hayes JD.

Free Radic Biol Med. 2015 Nov;88(Pt B):108-146. doi: 10.1016/j.freeradbiomed.2015.06.021. Epub 2015 Jun 27. Review.

49.

The emerging role of Nrf2 in mitochondrial function.

Dinkova-Kostova AT, Abramov AY.

Free Radic Biol Med. 2015 Nov;88(Pt B):179-188. doi: 10.1016/j.freeradbiomed.2015.04.036. Epub 2015 May 11. Review.

50.

New Monocyclic, Bicyclic, and Tricyclic Ethynylcyanodienones as Activators of the Keap1/Nrf2/ARE Pathway and Inhibitors of Inducible Nitric Oxide Synthase.

Li W, Zheng S, Higgins M, Morra RP Jr, Mendis AT, Chien CW, Ojima I, Mierke DF, Dinkova-Kostova AT, Honda T.

J Med Chem. 2015 Jun 11;58(11):4738-48. doi: 10.1021/acs.jmedchem.5b00393. Epub 2015 May 20.

PMID:
25965897

Supplemental Content

Loading ...
Support Center